

1. Record Nr.	UNINA9910817036303321
Titolo	The competitive status of the U.S. pharmaceutical industry : the influences of technology in determining international industrial competitive advantage // prepared by the Pharmaceutical Panel Committee on Technology and International Economic and Trade Issues, Office of the Foreign Secretary National Academy of Engineering, Commission on Engineering and Technical Systems National Research Council ; Charles C. Edwards, chairman ; Lacy Glenn Thomas, rapporteur
Pubbl/distr/stampa	Washington, D.C. ; ; [Great Britain], : National Academy Press, 1983
ISBN	1-280-24696-0 9786610246960 0-309-57203-7 0-585-21783-1
Edizione	[1st ed.]
Descrizione fisica	1 online resource (114 p.)
Altri autori (Persone)	EdwardsCharles C
Disciplina	338.4761510973
Soggetti	Pharmaceutical industry - Technological innovations - United States Pharmaceutical industry - United States Competition - United States Drugs - United States - Marketing
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	The Competitive Status of the U.S. Pharmaceutical Industry -- Copyright -- Preface -- Contents -- Summary -- FINDINGS ON THE U. S. COMPETITIVE POSITION -- DETERMINANTS OF NATIONAL PHARMACEUTICAL COMPETITIVE ADVANTAGE -- OPTIONS FOR AMERICAN POLICY -- Trade Options -- Domestic Economic Options -- Regulatory Options -- 1 Overview of U.S. Pharmaceutical Industry -- EMERGENCE OF THE MODERN PHARMACEUTICAL INDUSTRY -- NATURE OF PHARMACEUTICAL COMPETITION -- BENEFITS AND RISKS OF TECHNICAL CHANGE -- OVERVIEW AND LIMITATIONS OF THIS STUDY -- NOTES -- 2 Competitive Position of the U.S. Pharmaceutical Industry -- RESEARCH -- INNOVATION -- PRODUCTION -- SALES -- STRUCTURE

-- TRADE -- SUMMARY -- NOTES -- 3 Determinants of National  
Pharmaceutical Competitive Advantage -- LABOR COSTS -- MARKET  
GROWTH -- NATIONAL SCIENTIFIC CAPACITY -- GENERAL RELATIVE  
DECLINE OF U.S. INDUSTRY -- INDUSTRIAL POLICY: REGULATION --  
Greater Use of Expert Committees -- Greater Acceptance of Foreign  
Data -- Less Politicization of Drug Approval Process -- Greater  
Cooperation between Regulators and Industry -- INDUSTRIAL POLICY:  
TAXATION -- INDUSTRIAL POLICY: TRADE -- SUMMARY -- NOTES -- 4  
New Developments Affecting the Industry -- SCIENTIFIC ADVANCES --  
JAPANESE DEVELOPMENTS -- NOTES -- 5 Options for American  
Industrial Policy -- TRADE OPTIONS -- DOMESTIC ECONOMIC OPTIONS  
-- REGULATORY OPTIONS -- The IND Process -- Early Clinical Research  
-- Objectives of Investigational Drug Regulation -- Clinical  
Development Studies -- Preclearance of Clinical Research -- The NDA  
Process -- Application of the Standards for Drug Approval -- The NDA  
Submission and Its Review -- Utilization of Outside Expert Advice --  
Application of the Standards for Drug Approval -- FDA Management --  
Resources for the New Drug Review Process -- Improving Interactions  
with Industry.  
Tracking the Review Process to Ensure Timeliness -- Conflict of Interest  
and Expert Advisers -- Improving Interactions with Industry -- NOTES  
-- 6 Biographical Sketches -- Index.

---